S&P Futures
3,981.75 +3.75 (+0.09%) Dow Futures
32,344.00 +25.00 (+0.08%) Nasdaq Futures
12,861.25 +7.25 (+0.06%) Russell 2000 Futures
1,739.10 +6.60 (+0.38%) Crude Oil
69.77 -0.19 (-0.27%) Gold
1,994.80 -1.10 (-0.06%)
Surface Oncology, Inc. (SURF)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6327 |
| Open | 0.6800 |
| Bid | 0.6100 x 1400 |
| Ask | 0.6900 x 1000 |
| Day's Range | 0.6200 - 0.6900 |
| 52 Week Range | 0.6020 - 3.1700 |
| Volume | |
| Avg. Volume | 246,261 |
| Market Cap | 37.651M |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | 0.40 |
| EPS (TTM) | 1.5660 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.40 |
- GlobeNewswire
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company’s fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl. Details on the p
- Simply Wall St.
Surface Oncology Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Surface Oncology ( NASDAQ:SURF ) Full Year 2022 Results Key Financial Results Revenue: US$30.0m (up by US$27.3m from FY...
- GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into the third quarter of 2024 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor micro
